A Large Osteoid Osteoma of Trapezium: A Regenerative Approach and a Review of Literature

Pasquale Gravina, MD, *, † Francesco De Francesco, MD, * Pier Paolo Pangrazi, MD, * Antonio Gigante, MD, † Michele Riccio, MD

* Department of General and Specialties Surgery, Department of Plastic and Reconstructive Surgery-Hand Surgery Unit, Azienda Ospedaliera Universitaria (University Hospital) “Ospedali Riuniti,” Ancona, Italy
† Clinical Orthopedics, Department of Clinical and Molecular Science, Polytech University of Marche, Ancona, Italy

Osteoid osteoma is a benign bone tumor that usually grows in the long bones of the body and arises from osteoblasts and some components of osteoclasts. It represents the third most frequent type of benign bone tumors, accounting for 11% to 14% of the tumors. The entity usually involves the proximal femur and tibia. It has also been reported in the hand, especially the scaphoid, capitate, and proximal phalanx. The most common symptom is pain, usually during the night, relieved by the use of salicylates and nonsteroidal anti-inflammatory drugs. To date, only 5 cases involving the trapezium have been reported. This article describes a rare case of a large (1.3 cm) osteoid osteoma of the trapezium in a young male patient treated surgically with resection and curettage of the osteoid and provides a review of the existing literature.
A 19-year-old man was referred to our hospital with a history of intense pain localized at the right thumb basal joint for 1 year. The pain was characterized as dull and persistent and was not relieved with NSAIDs. During the first visit, the patient demonstrated limited thumb opposition with a Kapanji score of 5, a weak pinch test with 5-kg strength (20 kg on the other hand), and difficulty in daily activities.20 His visual analog scale (VAS) was 7, and the Michigan Hand Outcomes Questionnaire showed a value of 31.25%, with a high compromise of daily activities and pain (Table 1, 2).21 X-rays were negative for pathology (Fig. 1). Magnetic resonance imaging (MRI) showed an intense signal corresponding to the trapezium and a diffuse edema of the surrounding tissue (Fig. 2). A subsequent CT scan (Fig. 3) showed the typical image of the osteoid osteoma, with the presence of the sclerotic nidus surrounded by a cortical reaction. At this point, the patient was counseled on surgery for enucleation of the tumor and grafting with bioglass.

For the surgical procedure, we accessed the tumor with an S incision made on the radial volar side of the first ray. We deroofed the trapezium, isolating the osteoid nidus and the sclerotic bone through a trail of holes made by K-wires (Fig. 4) and taking care not to interrupt the cortex of the trapezium. After enucleation of the nidus with the help of curettes, we filled the bone defect with bioglass mixed with fresh blood (Fig. 5). We reconstructed the capsule, closed the wound leaving a drain, and applied a short arm cast with the thumb included for 4 weeks. The lesion was sent for definitive histological examination, which gave us the diagnosis of osteoid osteoma (Fig. 6).

We followed up with the patient clinically and radiologically monthly for the first 3 months and at 1 year after surgery to rule out recurrence. In the follow-up, we reported the VAS, pinch test, and Kapanji scores (Table 1). At the latest follow-up, the VAS, Pinch test, and Kapanji scores improved ($P < .05$). For the subjective evaluation of the functional and aesthetic outcomes, the authors administered the brief Michigan Hand Outcomes Questionnaire to the patient (Table 2). The brief Michigan Hand Outcomes Questionnaire global score showed slightly better, but not significant, results at 30 days after surgery (37.5%, $P = .633$), whereas it significantly showed improvement at 60 days after surgery (70.83%, $P = .01$).

### Discussion

Osteoid osteoma is a benign osteoblastic lesion accompanied by severe pain relieved by salicylates and NSAIDs. It is frequent in individuals aged 10–20 years and in males.15 The most common locations are the femur and tibia, followed by the small bones of
Figure 1. X-ray examinations from months before and after surgery and at 30 days of follow-up. A–C Radiographs before surgery. The trapezium is quite similar in both hands, both in the anteroposterior and lateral view. A Anteroposterior view showing the standard trapezium. B Okay sign view showing the normal trapezium. C Magnified view of the trapezium. D–F Radiographs taken in the operating room at the end of the procedure with the cast including metacarpophalangeal joint. A hyperintense image of the trapezium is observed, which is due to the active bioglass applied in the bone cavity. D Anteroposterior view showing the trapezium filled with bioglass. The trapezium appears hyperintense. E Oblique view showing the trapezium filled with bioglass. F Magnified view of the trapezium. G–I Thirty days after surgery. The trapezium density is similar to that of the normal bone, demonstrating how bioglass is going to integrate. Note that some parts of the active bioglass outside the trapezium will be absorbed in the following months. G Anteroposterior view showing the trapezium filled with bioglass. H Oblique view showing the trapezium filled with bioglass. I Magnified view of the trapezium. J One-year follow-up (front view). The appearance of the trapezius is similar to that of a normal trapezius in terms of density and joint relationships with the other carpals. K One-year follow-up (lateral view). The appearance of the trapezius is similar to that of a normal trapezius in terms of density and joint relationships with the other carpals.
the hand, feet, and spine. It can be found in the bone cortex, subcortical, intracortical, and intraperitoneal, and can rarely occur with more nidus in 1 or more bones. The reason for remission after the use of NSAIDs is that nidus osteoblasts display a diffusion of cyclooxygenase-2, an enzyme important for prostaglandin production, in particular prostaglandin E2. This enzyme is the main cause of pain and explains why the tumor is so responsive to cyclooxygenase-2 inhibitors (NSAIDs). This lesion can be confused with osteoblastoma, a similar tumor of bigger size, usually more than 1.5 cm. This tumor is characterized by irregular sclerosis, and the nidus is not well-defined. It does not typically regress and does not respond to NSAIDs. Another important condition that can be confused with osteoid osteoma is Brodie’s abscess. Plain radiographs are usually the first examinations performed and can show a small radiolucent area, corresponding to the nidus, surrounded by a sclerotic bone area. However, if the tumor is intramedullary, it may not show the surrounding bone sclerosis. The diagnosis of osteoid osteoma is usually suspected when CT scans show the nidus. A highly specific and sensitive finding in diagnosis is the presence of fine, low density, linear, vascular channels surrounding the osteoid osteoma. Furthermore, CT has better accuracy than plain radiography and MRI. Magnetic resonance imaging is usually the first examination performed and can show a small radiolucent area, corresponding to the nidus, surrounded by a sclerotic bone area. However, if the tumor is intramedullary located, it may not show that surrounding bone sclerosis. Although not as useful, an MRI examination can clearly show bone marrow edema and periarticular fluid. Care must be taken because the reactive soft tissue mass can be misinterpreted as a malignant tumor of the soft tissue or osteomyelitis. Thus, MRI images should not be assessed without CT and x-ray image references. Bone scintigraphy shows a vascular nidus in the arterial phase with a delayed phase within the surrounding reactive bones; the nidus is usually more intense, and the reactive bone is less intense; this is known as the “double density sign,” and it is diagnostic of osteoid osteoma. In 2010, Bostan et al described a case of osteoid osteoma in a 25-year-old patient with a 12-month history of wrist pain, which occurred particularly at night. The patient was initially treated with orthoses and NSAIDs without success. At the clinical examination, swelling was observed over the dorsoradial aspect of the hand. CT examination showed the sclerotic nidus...
surrounded by a radiolucent osteoid tissue, and MRI examination showed bone marrow edema associated with a focal lesion of the trapezium hypointense. The patient was treated with excisional biopsy, and after surgery, the patient had immediate pain improvement, and no recurrence was observed in follow-up. In 2017, Park et al. described an osteoid osteoma tumor in a 29-year-old patient initially treated for calcification periarthritis with several steroid injections until follow-up, debridement with no effect, until an ulnar deviated x-ray examination showed a sclerotic bone lesion, suspicious for osteoid osteoma and treated with curettage. The patient experienced immediate improvement in clinical pain and no recurrence at a 1-year follow-up. In 2017, Roberts et al. described a case of a 34-year-old woman with osteoid osteoma initially confused with carpometacarpal arthritis. In this case, an MRI scan showed a hypointense circular lesion along the dorsal aspect of the trapezium, and a CT study was
conducted to better characterize the lesion. The lesion was treated with curettage, and the diagnosis was confirmed by histopathology. After excision, the patient experienced complete pain relief and did not have any recurrence. In this study, because of the unusually large tumor size of 1.3 cm, we filled the bone loss with bioactive glass to avoid donor morbidity in such a young patient. There are many kinds of bioactive glasses, and we elected to use GlassBONE (Noraker) in 2 different formulations, “granules” to fill the bone defect and “putty,” a formulation with glycol polyethylene and glycerol, which grants ligand property useful for roofing the filled area. Bioglass is a bone substitute, first used in hand surgery by Hench et al in 1967; it is a bioactive material that can bond to the bone because of a specific chemical reaction. A bioactive material does not cause minimal rejection, is recognized as a biological material, and bonds with the tissue for mechanical interference. It is composed of silicon dioxide, calcium oxide, sodium oxide, and phosphoric anhydride; the equilibrium among these components makes the bioglass active. The gold standard of bioactive glass is the 45S5 (comprising 45% of silicon dioxide, 24.5% of sodium oxide, 24.5% of calcium oxide, and 6% of phosphorus pentoxide). When the bioactive glass is in contact with biological fluids, several chemical reactions cause silicon hydrolysis, creating a silica gel layer similar to the bone hydroxypatite (carbonated hydroxypatite). The carbonated hydroxypatite layer absorbs growth factors; these factors attract the M2 macrophages that promote lesion healing and attract staminal mesenchymal cells, which become the osteoblasts.

This process starts generating and depositing proteins of the extracellular bone matrix (collagen I). To conclude, bioactive glass causes osteoblasts and osteocytes to spread along the glass surface; this means that the material is mainly osteoconductive. In this study, after the tumor excision, the bone loss had to be filled, and we chose a bioglass to avoid donor site morbidity.

Conclusion

Analyzing the reports in the literature, we can conclude that osteoid osteoma should be suspected when a patient presents with long-lasting wrist pain with unclear diagnosis, associated with radial side tenderness surrounding the thumb, night pain responsive to NSAIDs, and negative x-rays. The approach has to start with a clinical examination, including the Kapanjadi test, which shows a reduction of thumb opposition compared with the contralateral hand. Although x-rays can be negative, a CT scan can provide us with the most accurate image of a nidus, whereas an MRI image can show bone edema and surrounding tissue inflammation and exclude other pathologies. A definitive diagnosis is made by histological examination. In our opinion, the best treatment is the curettage of the osteoid osteoma, avoiding transepicondyloidity if the carpometacarpal joint is not involved. If the lesion is larger in size, bone grafting, bone substitutes, or bioglass can be useful. The patient typically shows pain relief after surgery and should be followed monthly for 3 months after surgery, and at 6 months to a year with a CT scan to rule out recurrence, then new clinical and radiological control after 3 months and a final control made with CT examination after other 6 months to exclude recurrence.

References

1. Unni KK. Osteoid osteoma. In: Unni KK, ed. Dahlin’s Bone Tumors: General Aspects and Data on 11,087 Cases. LippincottRaven Publishers; 1996:121–130.
2. Campanacci M. Osteoid osteoma. In: Campanacci M, ed. Bone and Soft Tissue Tumors. Piccin Nuova Libreria S.p.A.; 1999:391–414.
3. Frassica FJ, Waltrip RL, Spanseller PD, Ma LD, McCarthy EF Jr. Clinicopathologic features and treatment of osteoid osteoma and osteoblastoma in children and adolescents. Orthop Clin North Am. 1996;27(3):559–574.
4. Murray PM, Berger RA, Inwards CY. Primary neoplasms of the carpal bones. J Hand Surg Am. 1999;24(5):1008–1013.
5. Moberg E. The natural course of osteoid osteoma. J Bone Joint Surg Am. 1951;33(1):166–170.
6. Golding JS. The natural history of osteoid osteoma; with a report of twenty cases. J Bone Joint Surg Br. 1954;36-B(2):218–229.
7. Kneifl JS, Simon MA. Medical management compared with operative treatment for osteoid-osteoma. J Bone Joint Surg Am. 1992;74(2):179–185.
8. Pettine KA, Klassen RA. Osteoid-osteoma and osteoblastoma of the spine. J Bone Joint Surg Am. 1986;68(3):354–361.
9. Poyser AB, Makley JT, Callewaert CC, Brackett R, Carter JR, Abdul-Karim FW. Osteoma of the long bones and the spine. A study of eleven patients and a review of the literature. J Bone Joint Surg Am. 1996;78(8):1172–1180.
10. Gitelis S, Schajowicz F. Osteoid osteoma and osteoblastoma. Orthop Clin North Am. 1989;20(3):313–325.
11. Towbin R, Kaye R, Meza MP, Pollock AN, Yaw K, Moreland M. Osteoid osteoma: percutaneous excision using a CT-guided coaxial technique. AJR Am J Roentgenol. 1995;164(4):945–949.
12. Lenke LG, Sutherland CJ, Gilula LA. Osteoid osteoma of the proximal femur: CT-guided preoperative localization. Orthopedics. 1994;17(3):289–292.
13. De Filippo M, Russo U, Papapetrou V, et al. Radiofrequency ablation of osteoid osteoma. Acta Biomed. 2018;89(1-5):175–185.
14. Hundleby JD. Osteoid osteoma of the trapezium. First case report of roentgenographically demonstrated progression in the trapezium. Clin Orthop Relat Res. 1976;116:170–172.
15. Hekkilä JT, Kukkonen J, Aho AJ, Moisander S, Kyyronen T, Mattila K. Bioactive glass granules: a suitable bone substitute material in the operative treatment of depressed lateral talib plateau fractures: a prospective randomized 1-year follow-up study. J Mater Sci Mater Med. 2011;22(4):1073–1080.
16. Camargo AFF, Baptista AM, Natalino R, de Camargo OP. Bioactive glass in cavitory bone defects: a comparative experimental study in rabbits. Acta Ortop Bras. 2015;23(4):202–207.
17. Schepers E, de Clercq M, Ducheyne P, Kempeeneers R. Bioactive glass particulate material as a filter for bone lesions. J Oral Rehabil. 1991;18(5):439–452.
18. Lindfors NC, Koski I, Hekkilä JT, Mattila K, Aho AJ. Bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors. J Biomed Mater Res B Appl Biomater. 2009;90(1):131–136.
19. Lindfors NC, Koski I, Hekkilä JT, Mattila K, Aho AJ. A prospective randomized 14-year follow-up study of bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors. J Biomed Mater Res B Appl Biomater. 2010;94(1):157–164.
20. Kapandji A. Clinical test of apposition and counter-apposition of the thumb. *Ann Chir Main*. 1986;5(1):67–73.

21. Waljee JF, Kim HM, Burns PB, Chung KC. Development of a brief, 12-item version of the Michigan Hand Questionnaire. *Plast Reconstr Surg*. 2011;128:208–220.

22. Jaffe HL, Lichtenstein L. Osteoid osteoma: further experience with this benign tumor of bone. With particular reference to cases showing the lesion about shaft cortices and commonly misclassified as instances of sclerosing non-suppurative osteomyelitis or cortical bone abscess. *J Bone Joint Surg Am*. 1940;22:645–682.

23. Mungo DV, Zhang X, O’Keefe RJ, Rosier RN, Puzas JE, Schwarz EM. COX-1 and COX-2 expression in osteoid osteomas. *J Orthop Res*. 2002;20(1):154–159.

24. Carpintero-Benitez P, Aguirre MA, Serrano JA, Lluch M. Effect of rofecoxib on pain caused by osteoid osteoma. *Orthopedics*. 2004;27(11):1188–1191.

25. Sim FH, Dahlin CD, Beabout JW. Osteoid osteoma: diagnostic problems. *J Bone Joint Surg Am*. 1975;57(2):154–159.

26. Gelman B. Radiology of bone tumors. *Orthop Clin North Am*. 1989;20(3):287–312.

27. Dorfman HD, Czerniak B. Bone cancers. *Cancer*. 1995;75(1 suppl):203–210.

28. Tumeh SS. Scintigraphy in the evaluation of arthropathy. *Radiol Clin North Am*. 1996;34(2):215–223.

29. Liu PT, Kojak JL, Roberts CC, de Chadarevian JP. The vascular groove sign: a new CT finding associated with osteoid osteomas. *AJR Am J Roentgenol*. 2011;196(1):168–173.

30. Pikoulas C, Mantzikopoulos G, Thanos L, Passomenos D, Dalamarinis C, Glambedaki-Dagianta K. Unusually located osteoid osteomas. *Eur J Radiol*. 1995;20(2):120–125.

31. Thompson GH, Wong KM, Konsens RM, Vibhabak S. Magnetic resonance imaging of an osteoid osteoma of the proximal femur: a potentially confusing appearance. *J Pediatr Orthop*. 1990;10(6):800–804.

32. Woods ER, Martel W, Mandell SH, Crabbe JP. Reactive soft-tissue mass associated with osteoid osteoma: correlation of MR imaging features with pathologic findings. *Radiology*. 1993;186(1):221–225.

33. Ehara S, Rosenthal DI, Aoki J, et al. Peritumoral edema in osteoid osteoma on magnetic resonance imaging. *Skelet Radiol*. 1999;28(5):265–270.

34. Assoum J, Railhac JB, Bonneville P, et al. Osteoid osteoma: percutaneous resection with CT guidance. *Radiology*. 1993;188(2):541–547.

35. Smith FW, Gilday DL. Scintigraphic appearances of osteoid osteoma. *Radiology*. 1980;137(1 Pt 1):191–195.

36. Helms CA, Hattner RS, Vogler JB III. Osteoid osteoma: radionuclide diagnosis. *Radiology*. 1984;151(3):779–784.

37. Bostan B, Sen C, Gunes T, Erdem M, Koseoglu RD. Osteoid osteoma of the trapezium: case report. *J Hand Surg*. 2010;35(4):636–638.

38. Park JH, Kang TW, Park JW. Unusual cause of the thumb basal joint pain: osteoid osteoma of the trapezium. *Arch Orthop Trauma Surg*. 2017;137(6):875–878.

39. Roberts SE, Mirzabegi MN, Naik A, Preciado C, Chang B. Osteoid osteoma of the trapezium: case report of an unusual tumor location presenting a diagnostic challenge. *Case Rep Orthop*. 2017;2017:3683854.

40. Cannio M, Bellucci D, Roether JA, Boccaccini DN, Cannillo V. Bioactive glass applications: a literature review of human clinical trials. *Materials (Basel)*. 2021;14(18):5440.

41. Hench LL. Splinter RJ, Allen WC, Greenlee TK. Bonding mechanisms at the interface of ceramic prosthetic materials. *J Biomed Mater Res*. 1971;5(6):117–141.

42. Hench LL. Bioceramics: from concept to clinic. *J Am Ceram Soc*. 1991;74:1487–1510.

43. Hench LL, Polak JM. Third-generation biomedical materials. *Science*. 2002;295(5557):1014–1017.

44. Hench LL, Ethridge AC. *Biomaterials: An Interfacial Approach*. Academic Press; 1982.

45. Hench LL, Paschall HA. Direct chemical bond of bioactive glass-ceramic materials to bone and muscle. *J Biomed Mater Res*. 1973;7(3):25–42.

46. Ono K, Yamasu T, Nakamura T, Kukoku T. Quantitative study on osteoconduction of apatite-wollastonite containing glass ceramic granules, hydroxyapatite granules, and alumina granules. *Biomaterials*. 1990;11(4):265–271.